Romidepsin

Create: 12/10/2018

Expired Date:	never
Category:	Health&Medical&Pharmaceutical
Message:	Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated. https://www.creative-peptides.com/product/romidepsin-item-10-101-186-33671.html






City:	Shirley[US]
Location:

Aug 09 2019	HLA-A_24_02 CMV pp65 tetramer-QYDPVAALF-PE labeled	449
Aug 09 2019	H-2Db LCMV gp33 tetramer-KAVYNFATC-APC labeled	464
Aug 09 2019	H-2Kb TRP-2 tetramer-SVYDFFVWL-PE labeled	439
Aug 09 2019	H-2Db WT1 tetramer-RMFPNAPYL-PE labeled	361
Aug 09 2019	H-2Kb HBV core tetramer-MGLKFRQL-APC labeled	443
Aug 09 2019	T-Select H-2Kb Negative (SIY) tetramer-SIYRYYGL-PE labeled	419
Aug 09 2019	T-Select H-2Kb MuLV p15E tetramer-KSPWFTTL-PE labeled	447
Aug 09 2019	T-Select H-2Kb OVA tetramer-SIINFEKL-APC labeled	477
Aug 09 2019	T-Select HLA-A_24_02 survivin-2B tetramer-AYACNTSTL-APC labeled	416
Aug 09 2019	T-Select HLA-A_02_01 CMV pp65 tetramer-NLVPMVATV-PE labeled	446